Cargando…

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model

Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux(®)) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gustafsson, H., Kale, A., Dasu, A., Lund, A., Edqvist, P.-H., Roberg, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691101/ https://www.ncbi.nlm.nih.gov/pubmed/28756482 http://dx.doi.org/10.1007/s12013-017-0814-5

Ejemplares similares

EPR Oximetry Sensor—Developing a TAM Derivative for In Vivo Studies
por: Boś-Liedke, Agnieszka, et al.
Publicado: (2017)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
por: Matic, Natasa, et al.
Publicado: (2019)

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
por: Kondo, T, et al.
Publicado: (2016)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Application of Electron Paramagnetic Resonance (EPR) Oximetry to Monitor Oxygen in Wounds in Diabetic Models
por: Desmet, Céline M., et al.
Publicado: (2015)

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
por: Magnes, Teresa, et al.
Publicado: (2017)

Evaluation of a nurse-led aftercare intervention for patients with head and neck cancer treated with radiotherapy and cisplatin or cetuximab
por: Braat, Cora, et al.
Publicado: (2022)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2019)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer
por: Schmitz, Sandra, et al.
Publicado: (2015)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
por: Borel, Christian, et al.
Publicado: (2018)

Effect of amifostine, a radiation-protecting drug, on oxygen concentration in tissue measured by EPR oximetry and imaging
por: Ueno, Megumi, et al.
Publicado: (2017)

Some EPR Signals in Tumour Tissue
por: Dodd, N. J. F.
Publicado: (1973)

Infectious Complications in Head and Neck Cancer Patients Treated with Cetuximab: Propensity Score and Instrumental Variable Analysis
por: Lee, Ching-Chih, et al.
Publicado: (2012)

The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
por: Pickhard, Anja, et al.
Publicado: (2014)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
por: Maahs, Lucas, et al.
Publicado: (2022)

Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
por: Kim, Hye Ryun, et al.
Publicado: (2020)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer
por: Bouhaddou, Mehdi, et al.
Publicado: (2021)

The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
por: Liu, Rin, et al.
Publicado: (2021)

Two Cases of Pneumatosis Intestinalis during Cetuximab Therapy for Advanced Head and Neck Cancer
por: Miller, James A., et al.
Publicado: (2015)

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
por: Nowsheen, Somaira, et al.
Publicado: (2011)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
por: Dequanter, Didier, et al.
Publicado: (2010)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
por: Krishnamurthy, Sapna, et al.
Publicado: (2022)

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines
por: Gomes, Izabela N. F., et al.
Publicado: (2022)

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
por: Iida, Mari, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agmafs69bt3j13a1ns6go65a1j